CHR Velocity as a predictor of early molecular response in patients with chronic myeloid leukemia.

被引：1
|
作者：
Malhotra, Pankaj
Chikkodi, Santosh V.
Naseem, Shano
Khadwal, Alka
Prakash, Gaurav
Kumari, Savita
Suri, Vikas
Varma, Neelam
Varma, Subhash
机构：
[1] PGIMER, Chandigarh, India
[2] Nehru Hosp, Chandigarh, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e18038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18038
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
    Yuji Okamoto
    Mitsuhito Hirano
    Kai Morino
    Masashi K. Kajita
    Shinji Nakaoka
    Mayuko Tsuda
    Kei-ji Sugimoto
    Shigehisa Tamaki
    Junichi Hisatake
    Hisayuki Yokoyama
    Tadahiko Igarashi
    Atsushi Shinagawa
    Takeaki Sugawara
    Satoru Hara
    Kazuhisa Fujikawa
    Seiichi Shimizu
    Toshiaki Yujiri
    Hisashi Wakita
    Kaichi Nishiwaki
    Arinobu Tojo
    Kazuyuki Aihara
    npj Systems Biology and Applications, 8
  • [32] Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
    Yeung, David T.
    Mauro, Michael J.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 240 - 243
  • [33] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE
    Castagnetti, F.
    Gugliotta, G.
    Breccia, M.
    Albano, F.
    Abruzzese, E.
    Levato, L.
    Cavazzini, F.
    Lurlo, A.
    Stagno, F.
    Ferrero, D.
    Porretto, F.
    Martino, B.
    Rupoli, S.
    Intermesoli, T.
    Fava, C.
    Pierri, I.
    Palandri, F.
    Venturi, C.
    Soverini, S.
    Luatti, S.
    Alimena, G.
    Pane, F.
    Martinelli, G.
    Saglio, G.
    Cavo, M.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2013, 98 : 59 - 59
  • [34] The Impact of Early Molecular Response in Event Free Survival in Patients with Chronic Myeloid Leukemia Treated with Imatinib
    Fogliatto, Laura
    Zanella Capra, Marcelo Eduardo
    Shaan, Mariza
    Costa, Tito Vanelli
    Torriani, Mayde Seadi
    Zanandrea Contin, Luis Carlos
    Breunig, Raquel
    Fassina, Katia
    Fernandes, Mario Sergio
    Almeida, Denise
    Schilling, Marco Antonio
    Hellwig, Tania
    Daltoe, Tiago
    Zardo, Adriana
    Moschen, Mariangela
    Nene, Moema
    Silveira, Juarez Fontoura
    Soares, Tahiane Brum
    Daudt, Liane Esteves
    Friedrisch, Joao
    Silla, Lucia
    BLOOD, 2014, 124 (21)
  • [35] Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia
    Abdallah, Aya M.
    Hafez, Hanafy
    Madney, Youssef
    Ahmed, Sonia
    Yassin, Dina
    Salem, Sherine
    Yousry, Rodina
    Abdel-Azim, Hisham
    Lehmann, Leslie
    Elhaddad, Alaa
    LEUKEMIA & LYMPHOMA, 2024, 65 (07) : 1024 - 1027
  • [36] Molecular response to imatinib in late chronic phase chronic myeloid leukemia. results of a phase II study by the Italian cooperative study group on chronic myeloid leukemia (ICSG on CML).
    Rosti, G
    Bassi, S
    Elena, T
    Testoni, N
    Amabile, M
    Martinelli, G
    Giannini, B
    De Vivo, A
    Luatti, S
    Bonifazi, F
    Izzo, B
    Salvatore, F
    Gottardi, E
    Cambrin, GR
    Cilloni, D
    Tiribelli, M
    Pane, F
    Russo, D
    Saglio, G
    Michele, B
    BLOOD, 2003, 102 (11) : 907A - 907A
  • [37] Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
    Hughes, Timothy P.
    Saglio, Giuseppe
    Kantarjian, Hagop M.
    Guilhot, Francois
    Niederwieser, Dietger
    Rosti, Gianantonio
    Nakaseko, Chiaki
    De Souza, Carmino Antonio
    Kalaycio, Matt E.
    Meier, Stephan
    Fan, Xiaolin
    Menssen, Hans D.
    Larson, Richard A.
    Hochhaus, Andreas
    BLOOD, 2014, 123 (09) : 1353 - 1360
  • [38] Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase
    Lee, Ji Yun
    Lim, Sung Hee
    Kim, Hae Su
    Yoo, Kwai Han
    Song, Haa-Na
    Cho, Jinhyun
    Park, Silvia
    Kim, Seok Jin
    Kim, Won Seog
    Kim, Kihyun
    Jang, Jun Ho
    Jung, Chul Won
    BLOOD, 2015, 126 (23)
  • [39] Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
    Hanfstein, B.
    Shlyakhto, V.
    Lauseker, M.
    Hehlmann, R.
    Saussele, S.
    Dietz, C.
    Erben, P.
    Fabarius, A.
    Proetel, U.
    Schnittger, S.
    Krause, S. W.
    Schubert, J.
    Einsele, H.
    Hanel, M.
    Dengler, J.
    Falge, C.
    Kanz, L.
    Neubauer, A.
    Kneba, M.
    Stegelmann, F.
    Pfreundschuh, M.
    Waller, C. F.
    Spiekermann, K.
    Baerlocher, G. M.
    Pfirrmann, M.
    Hasford, J.
    Hofmann, W-K
    Hochhaus, A.
    Mueller, M. C.
    LEUKEMIA, 2014, 28 (10) : 1988 - 1992
  • [40] Interferon associated vasculitis like syndrome in patients with chronic myeloid leukemia.
    AlZahrani, HA
    Lipton, J
    Minden, M
    Messner, H
    Sehdev, S
    BLOOD, 1997, 90 (10) : 3982 - 3982
12345